Abeona Therapeutics Inc. 8-K Filing
Ticker: ABEO · Form: 8-K · Filed: Apr 7, 2026 · CIK: 0000318306
| Field | Detail |
|---|---|
| Company | Abeona Therapeutics Inc. (ABEO) |
| Form Type | 8-K |
| Filed Date | Apr 7, 2026 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $50,000, $150,000 |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Abeona Therapeutics Inc. (ticker: ABEO) to the SEC on Apr 7, 2026.
What are the key financial figures in this filing?
Key dollar amounts include: $0.01 (nge on which registered Common Stock, $0.01 par value ABEO The Nasdaq Capital M); $50,000 (dan will receive an annual Board fee of $50,000 in cash and a one-time sign-on equity g); $150,000 (e sign-on equity grant in the amount of $150,000 worth of Company stock, in the form of).
How long is this filing?
Abeona Therapeutics Inc.'s 8-K filing is 2 pages with approximately 681 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 681 words · 3 min read · ~2 pages · Grade level 9.9 · Accepted 2026-04-07 08:35:30
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value ABEO The Nasdaq Capital M
- $50,000 — dan will receive an annual Board fee of $50,000 in cash and a one-time sign-on equity g
- $150,000 — e sign-on equity grant in the amount of $150,000 worth of Company stock, in the form of
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 11KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-26-015451.txt ( ) — 224KB
- abeo-20260401.xsd (EX-101.SCH) — 3KB
- abeo-20260401_lab.xml (EX-101.LAB) — 33KB
- abeo-20260401_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
01 Financial
Item 9.01 Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 7, 2026 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Abeona Therapeutics Inc. (Registrant) By: /s/ Joseph Vazzano Name: Joseph Vazzano Title: Chief Financial Officer Date: April 7, 2026